GE BioPharma sale to Danaher is complete

By The Science Advisory Board staff writers

April 1, 2020 -- The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

As part of Danaher, the business will be called Cytiva and will operate as a standalone company within Danaher's Life Sciences segment.

The deal, which was originally announced in February 2019, was completed with a cash consideration of around $20 billion to GE as well as Danaher's assumption of certain pension liabilities.

FTC greenlights $20B GE-Danaher deal
Following an agreement with the U.S. Federal Trade Commission (FTC), GE Healthcare Life Sciences is moving forward with the sale of its GE Biopharma business...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2nd Annual Cell Therapy Bioprocessing Conference
June 25-26
Boston, Massachusetts United States
BioProcess International Europe
July 13-16
Amsterdam, Noord-Holland Netherlands
Bioprocess International West
August 10-13
Santa Clara, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter